Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Exelixis
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Histologically confirmed advanced malignancy (solid tumor or lymphoma) that is metastatic or unresectable for which standard curative measures do not exist or are no longer effective
Eastern Cooperative Oncology Group (ECOG) performance status \</= 2
Life expectancy greater than 3 months
Adequate organ and marrow function
Written informed consent
Use of acceptable methods of contraception during the course of the study and for 3 months after completion of study
In the MTD expanded cohort: at least 20 subjects with metastatic and/or advanced/locally recurrent Medullary Thyroid Cancer not appropriate for surgical resection with measurable disease as defined by RECIST
You may not be if
Chemotherapy, immunotherapy or radiation within 4 weeks (or nitrosoureas or mitomycin C within 6 weeks) before the first scheduled dose of XL184
Administration of an investigational drug within 30 days of the first dose of XL184
Subject has not recovered from adverse events due to investigational agents or other medications administered more than 4 weeks before study enrollment
Known brain metastases
Uncontrolled intercurrent illness
Pregnancy or breastfeeding
Known HIV positive
Known allergy or hypersensitivity to any of the components of the XL184 formulation
Clareo Health | Study of XL184 (Cabozantinib) in Adults With Advanced Malignancies
